From: Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases
Gene panel type | Total patients run | Overall clinical sensitivity | Selected subgroup clinical sensitivity | |
---|---|---|---|---|
Cardiovascular | 243 | 28 % | Cardiomyopathy | 32 % |
Congenital heart disease | 10 % | |||
Arrhythmias | 31 % | |||
Aneurysms | 29 % | |||
Deafness | 147 | 54 % | Hearing loss | - |
Dermatology | 68 | 62 % | Various dermatological features | - |
Dysmorphology-Dysplasia | 354 | 38 % | Skeletal dysplasia | 45 % |
Dysmorphism | 32 % | |||
Endocrinology | 36 | 61 % | Pituitary and thyroid disorders | - |
Gastroenterology | 73 | 29 % | Persistent jaundice | - |
Hematology | 33 | 24 % | Aplastic anemia | - |
Inborn errors of metabolism | 122 | 59 % | Metabolic disorders | - |
Neurology | 524 | 40 % | Syndromic DD/ID (recognizable syndromes) | 47 % |
Syndromic DD/ID NYD (not yet determined, unrecognizable syndrome) | 25 % | |||
Structural brain (cerebral/cerebellar/brain stem) and spinal malformations/anomaliesa | 34 % | |||
Non-syndromic DD/ID NYD (not yet determined, unrecognizable)b | 11 % | |||
Neurodegenerative disorders | 42 % | |||
Coordinationc/movement disorders | 69 % | |||
Peripheral neuropathy | 33 % | |||
Myopathies/joint abnormalitiesd | 56 % | |||
PID | 196 | 37 % | Primary immunodeficiency disorders | - |
Pulmonology | 36 | 36 % | Chronic lung infection suspected cystic fibrosis | - |
Renal | 107 | 57 % | Glomerular/tubular disorders | 41 % |
Cystic kidney disease | 63 % | |||
Kidney malformation | 69 % | |||
Vision | 418 | 52 % | Retinal dystrophy (syndromic, non-syndromic, RP, CRD, macular dystrophy, FEVR, GFS) | 65 % |
Cataract (syndromic and non-syndromic) | 34 % | |||
Aniridia | 33 % | |||
Microphthalmia/anophthalmia (with and without coloboma) | 30 % | |||
Corneal dystrophy (CHED and all other subtypes) | 40 % | |||
Others | 23 % |